CStone Pharmaceuticals
CStone Pharmaceuticals (CSPHF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CSPHF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCStone Pharmaceuticals trailing twelve-month (TTM) revenue is $0.65B, a decrease of 35.51% year-over-year from $0.26B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.26B | -$0.14B | -35.51% |
| 2024-12-31 | $0.41B | -$0.06B | -12.21% |
| 2023-12-31 | $0.46B | -$0.02B | -3.64% |
| 2022-12-31 | $0.48B | +$0.24B | +97.51% |
| 2021-12-31 | $0.24B | -$0.80B | -76.54% |
| 2020-12-31 | $1.04B | +$1.04B | — |
| 2019-12-31 | $0.00B | -$0.01B | -100.00% |
| 2018-12-31 | $0.01B | +$0.00B | +21.84% |
| 2017-12-31 | $0.01B | +$0.01B | — |
| 2016-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare CSPHF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CStone Pharmaceuticals receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CStone Pharmaceuticals reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from CStone Pharmaceuticals's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CSPHF revenue · 4 questionsCSPHF's trailing twelve-month (TTM) revenue is $0.65B. That is a decrease of 35.51% year-over-year from $0.26B in FY2025.
▸ Source: FMP · CStone Pharmaceuticals SEC filings · GAAP · CStone Pharmaceuticals SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026